This article is a Preprint
Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.
Higher incidence of new atrial fibrillation in hospitalised COVID-19 patients compared to lower respiratory tract infection, however, less patients anticoagulated at discharge (preprint)
researchsquare; 2023.
Preprint
in English
| PREPRINT-RESEARCHSQUARE | ID: ppzbmed-10.21203.rs.3.rs-2458970.v1
ABSTRACT
Background Infection is a well-known contributor to developing cardiac arrythmias such as atrial fibrillation (AF), which contributes to over 25% of all ischaemic stroke. We wanted to quantify the incidence of first-diagnosed (new) AF (nAF) during hospitalisation with COVID-19 compared to a lower respiratory tract infection (LRTI), as well as compare anticoagulation rates at discharge, reasons for non-prescription of anticoagulation and determine factors associated with developing nAF with COVID-19. Methods We analysed a comprehensive hospital coding database on patients hospitalised due to COVID-19+/-AF or LRTI +/-AF, between 1/3/2020 and 31/12/2020 at a large tertiary hospital in the UK. Incidence of nAF during COVID-19 or LRTI, and the proportions of nAF patients discharged on anticoagulation and reasons for non-prescription from both cohorts were quantified. Results 2243 patients were hospitalised with LRTI and 488 with COVID-19. nAF was diagnosed in significantly more COVID-19 patients compared to LRTI (7.0% vs 3.6%, P=0.003). However, significantly less COVID-19 patients were discharged on anticoagulation compared to LRTI (19.2% vs 55.9%, P=0.003) despite similar CHA2DS2-VASc scores, and lower ORBIT scores. 14/26 LRTI +nAF patients had documented contraindication not to be anticoagulated, whereas only 1/12 patients with COVID-19 +nAF did. Patients who developed nAF during hospitalisation with COVID-19 were older (P<0.001), had pre-existing congestive cardiac failure (P=0.004), ischaemic heart disease (IHD) or peripheral vascular disease (PVD) (P<0.001), and a higher CHA2DS2-VASc score (P=0.02). Older age (Odds ratio (OR) 1.03, P=0.007) and IHD/PVD (OR 2.87, P=0.01) increased the odds of developing nAF with COVID-19. Conclusion Higher incidence of nAF and lower anticoagulation rates in COVID-19 patients were observed, compared to LRTI. A larger proportion of COVID-19 +nAF patients did not have a clear documented reason for non-prescription of anticoagulation in their notes. Whilst we await further research and clear guidelines, a pragmatic approach would be to holistically consider anticoagulation in all patients with COVID-19+nAF and a high ischaemic stroke risk.
Full text:
Available
Collection:
Preprints
Database:
PREPRINT-RESEARCHSQUARE
Main subject:
Arrhythmias, Cardiac
/
Respiratory Tract Infections
/
Atrial Fibrillation
/
Cerebral Infarction
/
Peripheral Vascular Diseases
/
Myocardial Ischemia
/
COVID-19
/
Heart Failure
Language:
English
Year:
2023
Document Type:
Preprint
Similar
MEDLINE
...
LILACS
LIS